Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06307795 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 10 → 15 locationsv7
  2. Study sites: 8 to 10 Eligibility criteria shortened, about 3 wordsv6 Show 1 more changeShow less
    • Eligibility criteria shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  3. Start date: Apr 20, 2024 to Jun 24, 2024v5
  4. Study sites: 4 to 8v4
  5. Study sites: 5 to 4v3
  6. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Apr 2024 to Apr 20, 2024 · Site details revised at 5 of 5 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Apr 2024 to Apr 20, 2024
    • Site details revised at 5 of 5 sites
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
Trial Details
NCT Number NCT06307795
Lead Sponsor Avistone Biotechnology Co., Ltd.
Conditions Locally Advanced or Metastatic Solid Tumors
Enrollment 63 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov